Takeda Biopharmaceuticals Launches Public Health Initiatives to Strengthen Health System for Rare Diseases in India
Takeda Biopharmaceuticals India Private Limited, a leading global biopharmaceutical company, has announced the launch of public health initiatives to strengthen the health system for rare diseases (RD) in India. These initiatives aim to enhance access to healthcare for rare disease patients who often face significant challenges such as childhood disabilities, reduced quality of life, and early mortality.
Under the leadership of Dr. Ruchi Sogarwal, Head of Corporate Affairs, Takeda India, the company has been actively working for the past two years to create awareness among various stakeholders in the healthcare sector about rare diseases and the policy provisions supporting affected patients. Additionally, Takeda has been experimenting with a Hub and Spoke capacity building and mentoring model to facilitate early diagnosis and effective management of rare diseases.
Partnership with stakeholders to raise awareness, facilitate early diagnosis, and explore sustainable funding options.
Takeda has partnered with reputable organizations such as APCO Worldwide, MAMTA Health Institute for Mother and Child, US-India Strategic Partnership Forum, and DakshamA Health and Education to ensure the successful implementation of these initiatives. Dr. Joyeta Ghoshal, Senior Associate Director at APCO Worldwide, expressed her satisfaction with the progress made so far, highlighting the need for a sustainable funding mechanism for rare disease patients.
Dr. Sunil Mehra, Executive Director of MAMTA Health Institute for Mother and Child, emphasized the significance of the health system in supporting rare disease patients. He praised the success of the Technical Support Unit (TSU) framework, which has facilitated partnerships and coordination among stakeholders in various health programs. The collaboration between MAMTA and Takeda aims to replicate these best practices for rare diseases, bringing together government bodies, Centers of Excellence (CoE), and medical institutions to strengthen the health system and improve access to healthcare.
Takeda’s public health initiatives for rare diseases in India are set to make a lasting impact on patients’ lives, raising awareness, enabling early diagnosis, and exploring sustainable funding options.